The new report by Expert Market Research titled, ‘United States HIV Drugs Market Growth, Report and Forecast 2021-2026, gives an in-depth analysis of the United States HIV Drugs Market, assessing the market based on its segments like types, drug class, route of administration and distribution channel.
The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porter’s Five Forces models.
Note 1: For a snapshot of the primary and secondary data of the market (2016-2026), along with business strategies and detailed market segmentation, please click on the request sample report. The sample report shall be delivered to you within 24 hours.
Get a Free Sample Report with Table of Contents – https://www.expertmarketresearch.com/reports/united-states-hiv-drugs-market/requestsample
The key highlights of the report include:
Market Overview (2016-2026)
- Historical Market Size (2020): USD 10 billion
The market’s growth would be aided by the increasing acceptance of advanced drugs. The United States is expected to benefit even more with the introduction of novel and modern combination drugs. The increased number of research and development programs for new drug releases, a well-established healthcare infrastructure, and the growing acceptance of innovative treatment alternatives by HIV infected people are all contributing to the region’s growth.
Explore full report with table of contents: https://www.expertmarketresearch.com/reports/united-states-hiv-drugs-market
Industry Definition and Major Segments
The human immunodeficiency virus is a chronic and life-threatening infection that can be passed from one person to another by blood or sexual intercourse. It’s a virus that targets CD-4 cells of the immune system, rendering the body vulnerable to pathogens and other diseases. The rising global prevalence of HIV disease has had a positive impact on the market for HIV medicines over the years. HIV drugs work by preventing the HIV from multiplying and thereby lowering the risk of infection.
On the basis of types of HIV drugs, the market is divided into:
- Antiretroviral Therapy (ART)
- Pre-Exposure Prophylaxis (Prep)
On the basis of drug class, the HIV market is segmented into:
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Nucleoside Reverse Transcriptase Inhibitors
- Multi-Class Combination Products
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors — CCR5 Co-Receptor Antagonist
- Fusion Inhibitors
The route of administration of the drugs in the include:
On the basis of distribution channel, the industry can be segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The United States HIV drugs market is being driven by the rise in HIV prevalence and the rate of treatment and diagnosis. Furthermore, government efforts to raise public concern about HIV’s origin, effects, appropriate treatment services, and the critical importance of these therapies in controlling the virus’s development are intensifying. As a result, the development of the HIV drugs industry is projected to be fueled by increased visibility as a result of such government initiatives.
However, the HIV drugs industry is likely to be constrained by government rules governing the approval and commercialization of HIV drugs.
Key Market Players
The major players in the market are AbbVie, AstraZeneca plc, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GlaxoSmithKline plc, Janssen Pharmaceuticals, Merck, Pfizer, Roche, Sun Pharma, ViiV Healthcare, and others. The report covers the market shares, plant turnarounds, capacities, investments, expansions and mergers and acquisitions, among other latest developments of these market players.
Expert Market Research (EMR) is a leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium-scale enterprises.
EMR customises syndicated reports according to client’s requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.
Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate, and actionable industry intelligence so that they may formulate informed, effective, and intelligent business strategies and ensure their leadership in the market.
Company Name: Claight Corporation
Contact Person: Frara Prih, Corporate Sales Specialist – U.S.A.
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA